LCTX (Lineage Cell Therapeutics) ROCE %: -29.98% (As of Mar. 2026)

What is Lineage Cell Therapeutics ROCE %?

Lineage Cell Therapeutics LCTX +0.79% 78 ROCE % is -29.98% as of Mar. 2026. GuruFocus rates LCTX with a GF Score™ of 78/100 and a GF Value™ of $1.33 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lineage Cell Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -29.98%.

Lineage Cell Therapeutics (AMEX:LCTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lineage Cell Therapeutics ROCE % Related Terms

Lineage Cell Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Lineage Cell Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lineage Cell Therapeutics ROCE % Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-43.24

-19.40

-26.35

-23.56

-21.73

Lineage Cell Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-26.30	-22.11	-18.89	-28.87	-29.98

78GF Score

Lineage Cell Therapeutics Inc LCTX

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lineage Cell Therapeutics ROCE % Calculation

Lineage Cell Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-21.779	/	( ( (113.218 - 13.977)	+	(112.584 - 11.367) )	/ 2 )
	=	-21.779	/	( (99.241	+	101.217)	/ 2 )
	=	-21.779	/	100.229
	=	-21.73 %

Lineage Cell Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-30.372	/	( ( (112.584 - 11.367)	+	(109.533 - 8.148) )	/ 2 )
	=	-30.372	/	( ( 101.217	+	101.385 )	/ 2 )
	=	-30.372	/	101.301
	=	-29.98 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -29.98% mean?

Lineage Cell Therapeutics (LCTX) has a ROCE % of -29.98% as of Mar. 2026.

Is Lineage Cell Therapeutics' ROCE % too high?

Lineage Cell Therapeutics' current ROCE % is -29.98%. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Lineage Cell Therapeutics' ROCE % compare to FATE and ABEO?

Lineage Cell Therapeutics' ROCE % of -29.98% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Lineage Cell Therapeutics's current ROCE % is -29.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lineage Cell Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.27 — trading 4.5% below its estimated fair value. The current ROCE % is -29.98%. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current ROCE % is -29.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of $1.27 is trading 4.5% below its estimated GF Value™ of $1.33. GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.

Key valuation signals for LCTX:

ROCE %: -29.98%
GF Value™: $1.33 vs. price of $1.27 (4.5% below fair value)
GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies FATE ABEO RCKT BCYC IVVD DMAC NMRA RZLT NAUT TENX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges LCTX:Israel BT3:Germany

Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

78GF Score

Get the complete analysis for LCTX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.27

Price

$1.33

GF Value

View LCTX Analysis

See ROCE % data for all stocks →